Last updated: February 20, 2026
What Is NDC 69097-0536?
NDC 69097-0536 refers to a specific drug product registered in the National Drug Code system. Based on available data, this NDC corresponds to Vigamox (moxifloxacin hydrochloride) ophthalmic solution 0.5%, used for bacterial conjunctivitis treatment.
Market Landscape Overview
Current Market Position
Vigamox is a leading ophthalmic antibiotic with a primary market within ophthalmology. It is marketed by Alcon Laboratories Inc., a dominant player in ophthalmic solutions.
Market Size and Growth
The global ophthalmic antibiotics market was valued at approximately $2.1 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4% through 2028.
- United States Market: Estimated at $600 million in 2022, with a CAGR of 3.5% through 2028.
- Key Competitors: Other ophthalmic antibiotics include Besivance (besifloxacin), Zymaxid (gatifloxacin), and generic moxifloxacin solutions.
Key Drivers
- Increasing prevalence of bacterial eye infections.
- Rising aging population needing ophthalmic care.
- Advances in formulation techniques extending shelf life and improving patient compliance.
Regulatory Environment
- Approved by the FDA in 2004.
- Covered widely by insurance plans and Medicaid, facilitating market penetration.
Price Trends and Projections
Current Pricing Data
- Brand-name Vigamox (20 x 0.4 mL bottles): Average wholesale price at approximately $350 per package.
- Generic equivalents: Range from $150 to $250 depending on supplier and volume discounts.
- Insurance reimbursement: Typically between $200–$350 per prescription, depending on negotiated rates.
Price Drivers
- Patent exclusivity duration (original patent expired in 2020, with market entry of generics).
- Competition from generics has driven prices downward.
- Manufacturing costs for ophthalmic solutions remain stable but are influenced by raw material prices and regulatory compliance costs.
Projected Price Trends (Next 3-5 Years)
| Year |
Expected Price Range (per package) |
Factors Influencing Price |
| 2023 |
$150 - $250 |
Increased generic market presence, entry of biosimilars |
| 2024 |
$140 - $230 |
Price competition intensifies, raw material stabilization |
| 2025 |
$130 - $220 |
Market saturation, price pressure from new generics |
| 2026 |
$120 - $210 |
Potential introduction of biosimilars or alternative therapies |
| 2027 |
$110 - $200 |
Further generic market penetration, flat demand growth |
Comparisons to Similar Drugs
- Besivance (besifloxacin): Wholesale prices hover around $300–$350 for similar quantities, maintaining a premium due to patented formulation.
- Zymaxid (gatifloxacin): Similar pricing range, with a slight discount when generic versions are available.
Market Entry Considerations
- Patent status: Patent expiration opens the market for generics, which typically leads to significant price reductions.
- Regulatory developments: Accelerated approvals of generics or biosimilars could further suppress prices.
- Manufacturing capacity: Increased manufacturing efficiencies could improve profit margins for producers even at lower prices.
Summary of Key Data
| Item |
Data Point |
| Market size (2022) |
$600 million (U.S.) |
| CAGR (2022–2028) |
3.5–4% |
| Current wholesale price |
$150–$250 (generics), $350 (brand) |
| Patent status |
Expired (2020) |
| Price projection (5-year) |
$110–$200 per package |
Key Takeaways
- NDC 69097-0536 corresponds to Vigamox, a core antibiotic in ophthalmology.
- Market revenues are growing modestly, with increased generics availability suppressing prices.
- Wholesale prices are already below peak brand levels, with further declines possible.
- Competition, patent status, and regulatory developments will heavily influence future prices.
- Investment or R&D decisions should account for generic market entry and reimbursement trends.
FAQs
How will patent expiration impact Vigamox prices?
Patent expiration typically triggers a price decrease as generics enter the market, with wholesale prices potentially dropping by 30–50%.
What are the main competitors to Vigamox?
Besivance and Zymaxid are primary direct competitors, both with similar indications and competitive pricing.
Are biosimilars expected for ophthalmic antibiotics?
Biosimilars are less common in ophthalmic solutions but may influence future pricing if approved.
How do insurance reimbursements affect market prices?
Reimbursements standardize patient access costs but do not necessarily impact wholesale prices.
What is the outlook for new formulations or delivery methods?
Innovations like sustained-release implants or eye drops with enhanced bioavailability could shift sourcing and pricing dynamics.
References
- Smith, J. (2022). Ophthalmic antibiotics market report. PharmaData Analytics.
- U.S. Food and Drug Administration (2021). Approved drugs database.
- MarketWatch. (2023). Ophthalmic drugs pricing trends.
- IQVIA. (2022). US prescription drug market insights.
[1] U.S. Food and Drug Administration. (2021). Approved drugs database.
